Amedeo Smart

Free Medical Literature Service

 

Amedeo

Antiretroviral Therapy
  Free Subscription

Articles published in
HIV Med
    September 2025
  1. ORLOVA-MOROZOVA E, Kireev D, Kirichenko A, Bobkov V, et al
    Real-world efficacy of bictegravir/emtricitabine/tenofovir alafenamide regimen in patients infected with HIV-1 sub-subtype A6 harbouring the L74I mutation.
    HIV Med. 2025;26:1463-1467.
    >> Share

    August 2025
  2. PIERONE G JR, Brunet L, Fusco JS, Sension MG, et al
    Suppressed switch to Bictegravir/emtricitabine/tenofovir alafenamide compared with dolutegravir/lamivudine: Real-world evidence from the OPERA cohort.
    HIV Med. 2025 Aug 30. doi: 10.1111/hiv.70105.
    >> Share

  3. MEYER SC, Klein Z, Schoepf IC, Thorball CW, et al
    Leukocyte count and new-onset diabetes mellitus in people with HIV: A longitudinal study.
    HIV Med. 2025 Aug 1. doi: 10.1111/hiv.70089.
    >> Share

    July 2025

  4. Weight gain on tenofovir alafenamide fumarate-based therapy compared to tenofovir disoproxil fumarate- and abacavir-based therapy in children and young people living with HIV in Europe.
    HIV Med. 2025 Jul 31. doi: 10.1111/hiv.70070.
    >> Share

    June 2025
  5. GHOSN J, Chow J, Gandhi M, Gorgolas M, et al
    Rapid start with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment in people with human immunodeficiency virus-1 (HIV-1): A systematic literature review of clinical and patient-reported outcomes.
    HIV Med. 2025 Jun 26. doi: 10.1111/hiv.70065.
    >> Share

    May 2025
  6. RASHID I, Unger NR, Willis C, Dhippayom T, et al
    Comparison of treatment-emergent resistance-associated mutations and discontinuation due to adverse events among integrase strand transfer inhibitor-based single-tablet regimens and cabotegravir + rilpivirine for the treatment of virologically suppres
    HIV Med. 2025 May 27. doi: 10.1111/hiv.70050.
    >> Share

  7. CARTIER A, Milinkovic A, Goodall L, Mora-Peris B, et al
    HIV seroconversions and genotypic viral resistance profiles in the PrEP impact trial.
    HIV Med. 2025 May 21. doi: 10.1111/hiv.70045.
    >> Share

    April 2025
  8. DE VITO A, Tavelli A, Cozzi-Lepri A, Giacomelli A, et al
    Safety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with HIV: Insights from the Icona cohort.
    HIV Med. 2025 Apr 28. doi: 10.1111/hiv.70037.
    >> Share

    March 2025
  9. AKSAK-WAS B, Skonieczna-Zydecka K, Parczewski M, Hrynkiewicz R, et al
    Rethinking HIV treatment: How non-integrase strand regimens may hold the key to better immune health.
    HIV Med. 2025 Mar 28. doi: 10.1111/hiv.70020.
    >> Share

  10. MARTORELL C, Ramgopal M, Hagins D, Osiyemi O, et al
    Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV-1 initiating first-line therapy: 5-year follow-up from two phase III studies.
    HIV Med. 2025 Mar 21. doi: 10.1111/hiv.70018.
    >> Share

  11. PINCUS KJ, Faridi N, Ryscavage PA, Seung H, et al
    Assessing weight change in adolescents and young adults with perinatally acquired HIV and integrase inhibitor use.
    HIV Med. 2025 Mar 20. doi: 10.1111/hiv.70019.
    >> Share

  12. SURIYARACHCHI DDC, Katuwavila NP
    Lipid nanoparticles in antiretroviral therapy: A nanotechnology breakthrough for HIV/AIDS treatment.
    HIV Med. 2025 Mar 4. doi: 10.1111/hiv.13770.
    >> Share

    February 2025
  13. BEGUELIN C, Surial B, Hofmann E, Begre L, et al
    Frequent hepatitis B surface antigen (HBsAg) clearance during tenofovir therapy in persons with HIV/hepatitis B virus coinfection.
    HIV Med. 2025 Feb 25. doi: 10.1111/hiv.13766.
    >> Share

  14. SALVO PF, Ciccullo A, Visconti E, Lombardi F, et al
    Impact of HBV serological status on HIV virological efficacy of two-drug antiretroviral regimens: A retrospective observational study on virologically suppressed people with HIV switching to lamivudine/dolutegravir.
    HIV Med. 2025 Feb 5. doi: 10.1111/hiv.13765.
    >> Share

    January 2025
  15. ODONGPINY EAL, Nicol M, Katana E, Owori J, et al
    A programmatic assessment of dolutegravir adverse events and discontinuations in Uganda.
    HIV Med. 2025 Jan 24. doi: 10.1111/hiv.13761.
    >> Share

  16. MCGARRITY MW, MacPherson P, Li A, Naccarato M, et al
    Intracellular tenofovir-diphosphate concentrations in HIV pre-exposure prophylaxis users who underwent bariatric surgery.
    HIV Med. 2025 Jan 15. doi: 10.1111/hiv.13759.
    >> Share

    December 2024
  17. VARMA A, Singh MP, Sah S, Verma A, et al
    Commentary on 'DORA: 48-week weight and metabolic changes in black women with HIV, in a phase IIIb switch study from dolutegravir- or efavirenz- to doravirine-based first-line antiretroviral therapy'.
    HIV Med. 2024 Dec 26. doi: 10.1111/hiv.13755.
    >> Share

    November 2024
  18. PENNER J, Ombajo LA, Nkuranga J, Otieno E, et al
    High prevalence of osteoporosis among virally suppressed older people (>/=60 years) living with HIV.
    HIV Med. 2024 Nov 21. doi: 10.1111/hiv.13741.
    >> Share

  19. KENIYOPOULLOS R, Khawaja AA, Boffito M, Emerson M, et al
    In vitro and patient studies with platelets to explore off-target cardiovascular effects of integrase inhibitors.
    HIV Med. 2024 Nov 15. doi: 10.1111/hiv.13738.
    >> Share

    October 2024
  20. STEPHAN C, Spinner CD, Rieke A, Christensen S, et al
    Effectiveness, safety, and patient-reported outcomes of emtricitabine/tenofovir alafenamide-based regimens for the treatment of HIV-1 infection: Final 24-month results from the prospective German TAFNES cohort study.
    HIV Med. 2024 Oct 30. doi: 10.1111/hiv.13728.
    >> Share

  21. FERNANDES G, Chappell E, Goetghebuer T, Kahlert CR, et al
    HIV postnatal prophylaxis and infant feeding policies vary across Europe: results of a Penta survey.
    HIV Med. 2024 Oct 23. doi: 10.1111/hiv.13723.
    >> Share

  22. ERON JJ, Ramgopal M, Osiyemi O, Mckellar M, et al
    Bictegravir/emtricitabine/tenofovir alafenamide in adults with HIV-1 and end-stage kidney disease on chronic haemodialysis.
    HIV Med. 2024 Oct 6. doi: 10.1111/hiv.13721.
    >> Share

    September 2024
  23. MENDES-FERREIRA AAC, Veras NMC, Pinho REGG, Pascom AR, et al
    HIV drug resistance, viral suppression, and survival in children living with HIV in Brazil.
    HIV Med. 2024 Sep 25. doi: 10.1111/hiv.13714.
    >> Share

  24. WOODS J, Sokhela S, Akpomiemie G, Bosch B, et al
    DORA: 48-week weight and metabolic changes in Black women with HIV, in a phase IIIb switch study from dolutegravir- or efavirenz- to doravirine-based first-line antiretroviral therapy.
    HIV Med. 2024 Sep 17. doi: 10.1111/hiv.13711.
    >> Share

  25. PINEIRO C, Policarpo S, Caldas C, Santos L, et al
    Real-world effectiveness and safety of switching to dolutegravir/lamivudine among people living with HIV-1 aged over 50 years who are virologically suppressed.
    HIV Med. 2024 Sep 6. doi: 10.1111/hiv.13699.
    >> Share

    May 2024
  26. KATLAMA C, Bisshop F, Bogner J, Perez Elias MJ, et al
    Efficacy and safety of dolutegravir/lamivudine in virologically suppressed female participants: week 48 data from the pooled TANGO and SALSA studies.
    HIV Med. 2024 May 17. doi: 10.1111/hiv.13643.
    >> Share

  27. BUSCA-ARENZANA C, Ortega-Gonzalez D, Diaz-Almiron M, Montes ML, et al
    Metabolic effects of switching to Biktarvy (B/F/TAF) in patients with HIV-1 treated with antiretroviral regimens that do not include tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF): The Metabic study.
    HIV Med. 2024 May 15. doi: 10.1111/hiv.13659.
    >> Share

    April 2024
  28. LLIBRE JM, Garcia F, Blanco JL, Pelaez EP, et al
    Prevalence of people living with multidrug-resistant HIV and limited treatment options in Spain.
    HIV Med. 2024 Apr 30. doi: 10.1111/hiv.13650.
    >> Share

  29. CALZA L, Giglia M, Colangeli V, Bon I, et al
    Improvement in insulin sensitivity after switching from an integrase inhibitor-based regimen to doravirine/tenofovir disoproxil fumarate/lamivudine in people with significant weight gain.
    HIV Med. 2024 Apr 3. doi: 10.1111/hiv.13644.
    >> Share

    March 2024
  30. SAWRY S, Ayalew K, Maimela G, Briggs-Hagen M, et al
    Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study.
    HIV Med. 2024 Mar 22. doi: 10.1111/hiv.13638.
    >> Share

  31. JACOBS TG, Okemo D, Ssebagereka A, Mwehonge K, et al
    Availability and stock-outs of paediatric antiretroviral treatment formulations at health facilities in Kenya and Uganda.
    HIV Med. 2024 Mar 18. doi: 10.1111/hiv.13635.
    >> Share

  32. DOU Y, Lu R, Su L, Lan K, et al
    Efficacy of dolutegravir + lamivudine q.d. with food in people with TB/HIV using a rifampicin-based regimen: A retrospective observational case series.
    HIV Med. 2024 Mar 17. doi: 10.1111/hiv.13632.
    >> Share

  33. FURSA O, Bannister W, Neesgaard B, Podlekareva D, et al
    SARS-CoV-2 testing, positivity, and factors associated with COVID-19 among people with HIV across Europe in the multinational EuroSIDA cohort.
    HIV Med. 2024 Mar 3. doi: 10.1111/hiv.13620.
    >> Share

    January 2024
  34. ROSSOTTI R, D'Amico F, Bana NB, Nava A, et al
    Durability of doravirine with dolutegravir dual regimen compared with other dolutegravir-based dual combinations.
    HIV Med. 2024 Jan 23. doi: 10.1111/hiv.13615.
    >> Share

  35. ARORA AK, Vicente S, Engler K, Lessard D, et al
    Impact of social determinants of health on time to antiretroviral therapy initiation and HIV viral undetectability for migrants enrolled in a multidisciplinary HIV clinic with rapid, free, and onsite B/F/TAF: 'The ASAP study'.
    HIV Med. 2024 Jan 11. doi: 10.1111/hiv.13608.
    >> Share

  36. KOH MCY, Ngiam JN, Yong J, Tambyah PA, et al
    The role of an artificial intelligence model in antiretroviral therapy counselling and advice for people living with HIV.
    HIV Med. 2024 Jan 2. doi: 10.1111/hiv.13604.
    >> Share

    December 2023
  37. ESSER S, Brunetta J, Inciarte A, Levy I, et al
    Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world insights from BICSTaR cohorts.
    HIV Med. 2023 Dec 26. doi: 10.1111/hiv.13593.
    >> Share

  38. RANZANI A, Castelli F, Di Biagio A, d'Arminio Monforte A, et al
    Influence of efavirenz and 8-hydroxy-efavirenz plasma levels on cognition and central nervous system side effects.
    HIV Med. 2023 Dec 17. doi: 10.1111/hiv.13600.
    >> Share

  39. MCGEE DM, Cotter AG
    HIV and fracture: Risk, assessment and intervention.
    HIV Med. 2023 Dec 12. doi: 10.1111/hiv.13596.
    >> Share

    October 2023
  40. WATERS L, Hassan Wada Y, Barber TJ
    International AIDS society conference 2023 summary.
    HIV Med. 2023 Oct 23. doi: 10.1111/hiv.13563.
    >> Share

  41. AMBROSIONI J, Levi L, Alagaratnam J, Van Bremen K, et al
    Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023.
    HIV Med. 2023 Oct 18. doi: 10.1111/hiv.13542.
    >> Share

  42. GACIC N, Tulloch K, Money D, Tkachuk S, et al
    Daily ritonavir-boosted darunavir for viral suppression in pregnancy (DRV-P).
    HIV Med. 2023 Oct 10. doi: 10.1111/hiv.13546.
    >> Share

  43. BEGRE L, Boyd A, Salazar-Vizcaya L, Suter-Riniker F, et al
    Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy.
    HIV Med. 2023 Oct 10. doi: 10.1111/hiv.13561.
    >> Share

  44. FRANGE P, Veber F, Burgard M, Blanche S, et al
    Bictegravir/emtricitabine/tenofovir alafenamide in paediatrics: Real-life experience from a French cohort (2019-2023).
    HIV Med. 2023 Oct 8. doi: 10.1111/hiv.13562.
    >> Share

    September 2023
  45. LUI GC, Wong GL, Yang HC, Sheng WH, et al
    Current practice and recommendations for management of hepatitis B virus in people living with HIV in Asia.
    HIV Med. 2023 Sep 21. doi: 10.1111/hiv.13545.
    >> Share

    August 2023
  46. SHENGIR M, Lebouche B, Elgretli W, Saeed S, et al
    Switch to a raltegravir-based antiretroviral regimen in people with HIV and non-alcoholic fatty liver disease: A randomized controlled trial.
    HIV Med. 2023 Aug 28. doi: 10.1111/hiv.13531.
    >> Share

    July 2023
  47. CHAN TY, Marta M, Rackstraw S
    Relapse of neurosymptomatic cerebrospinal fluid HIV RNA escape.
    HIV Med. 2023 Jul 24. doi: 10.1111/hiv.13527.
    >> Share

    June 2023
  48. ZINO L, Tack CJ, Richel O, Burger DM, et al
    GLP-1 agonists for people living with HIV and obesity, is there a potential?
    HIV Med. 2023 Jun 20. doi: 10.1111/hiv.13521.
    >> Share

  49. DEKOVEN S, Naccarato M, Brumme CJ, Tan DHS, et al
    Treatment-emergent reverse transcriptase resistance during antiretroviral therapy with bictegravir, tenofovir alafenamide, and emtricitabine: A case series.
    HIV Med. 2023 Jun 14. doi: 10.1111/hiv.13520.
    >> Share

    May 2023
  50. ROMO ML, Esber AL, Owuoth J, Maswai J, et al
    Impact of weight gain with dolutegravir on antiretroviral adherence and viral suppression in four African countries.
    HIV Med. 2023 May 25. doi: 10.1111/hiv.13501.
    >> Share

  51. PALMIER E, De Miguel R, Montejano R, Busca C, et al
    Three-year efficacy of switching to dolutegravir plus lamivudine: A real-world study.
    HIV Med. 2023 May 16. doi: 10.1111/hiv.13500.
    >> Share

    April 2023
  52. SURIAL B, Wandeler G
    Tenofovir alafenamide and weight: What do we still need to know to inform clinical decisions?
    HIV Med. 2023 Apr 24. doi: 10.1111/hiv.13497.
    >> Share

  53. FITZGERALD N, Coltart H, Dominguez L, Flanagan K, et al
    PrEP for women in Europe: a systematic literature review.
    HIV Med. 2023 Apr 23. doi: 10.1111/hiv.13458.
    >> Share

  54. NASREDDINE R, Florence E, Yombi JC, Henrard S, et al
    Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.
    HIV Med. 2023 Apr 10. doi: 10.1111/hiv.13493.
    >> Share

  55. HOCQUELOUX L, Menard A, Arvieux C, Joly V, et al
    Weight gain following the single substitution of tenofovir disoproxil fumarate by tenofovir alafenamide in HIV-infected people from the French Dat'AIDS cohort: A propensity score-matched analysis.
    HIV Med. 2023 Apr 4. doi: 10.1111/hiv.13488.
    >> Share

    March 2023
  56. DUNN K, Bushen J, Luo D, Cai J, et al
    Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive (AMBER) and virologically suppressed (EMERALD) participants with neurological and/or psychiatric comorbidities: Week 96 subgroup analysis.
    HIV Med. 2023;24:279-289.
    >> Share

  57. AVIHINGSANON A, Chetchotisakd P, Kiertiburanakul S, Ratanasuwan W, et al
    Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials.
    HIV Med. 2023;24:290-300.
    >> Share

    February 2023
  58. MOUNZER K, Brunet L, Fusco JS, McNicholl IR, et al
    Immune response to ART initiation in advanced HIV infection.
    HIV Med. 2023 Feb 15. doi: 10.1111/hiv.13467.
    >> Share

    November 2022
  59. MAGGI P, Ricci ED, Muccini C, Galli L, et al
    Subclinical atherosclerosis as detected by carotid ultrasound and associations with cardiac and HIV-specific risk factors; the Archi-Prevaleat project.
    HIV Med. 2022 Nov 30. doi: 10.1111/hiv.13448.
    >> Share

  60. BENDALA-ESTRADA AD, Diaz-Almiron M, Busca C, Mican R, et al
    Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir-based dual therapy. Bi-lipid study.
    HIV Med. 2022 Nov 16. doi: 10.1111/hiv.13432.
    >> Share

    October 2022
  61. PAPADOPOULOS A, Thomas K, Protopapas K, Antonyak S, et al
    HIV treatment strategies across Central, Eastern and Southeastern Europe: New times, old problems.
    HIV Med. 2022 Oct 4. doi: 10.1111/hiv.13416.
    >> Share


  62. IN BRIEF: BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022.
    HIV Med. 2022;23 Suppl 3:3-14.
    >> Share

    September 2022
  63. HIKASA S, Shimabukuro S, Hideta K, Higasa S, et al
    Comparison between the impact of tenofovir alafenamide and that of abacavir on rapid kidney function decline: A retrospective observational study.
    HIV Med. 2022 Sep 20. doi: 10.1111/hiv.13408.
    >> Share

  64. FULLER T, Fragoso da Silveira Gouvea MI, Benamor Teixeira ML, Ferreira Medeiros A, et al
    Real-world experience with weight gain among pregnant women living with HIV who are using integrase inhibitors.
    HIV Med. 2022 Sep 5. doi: 10.1111/hiv.13388.
    >> Share

    August 2022
  65. AKSAK-WAS BJ, Kowalska JD, Zabek P, Serwin K, et al
    Immune restoration affects 10-year survival in people living with HIV/AIDS.
    HIV Med. 2022 Aug 25. doi: 10.1111/hiv.13391.
    >> Share

  66. SHAFRAN SD, Hughes CA
    Bictegravir/emtricitabine/tenofovir alafenamide in patients with genotypic NRTI resistance.
    HIV Med. 2022 Aug 16. doi: 10.1111/hiv.13376.
    >> Share

  67. PERELLO R, Losada A, Chen J, Supervia A, et al
    Amphetamine-related intoxications in people living with HIV: An observational study in an emergency department in Barcelona (Spain) from 2018 to 2020.
    HIV Med. 2022 Aug 9. doi: 10.1111/hiv.13365.
    >> Share

  68. NASREDDINE R, Yombi JC, Darcis G, Florence E, et al
    Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium.
    HIV Med. 2022 Aug 8. doi: 10.1111/hiv.13373.
    >> Share

    June 2022
  69. BROWN JA, Nsakala BL, Mokhele K, Rakuoane I, et al
    Dolutegravir in real life: Self-reported mental and physical health outcomes after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy in a prospective cohort study in Lesotho.
    HIV Med. 2022 Jun 22. doi: 10.1111/hiv.13352.
    >> Share

    May 2022
  70. GIZAW A, King WC, Hinerman AS, Chung RT, et al
    A prospective cohort study of renal function and bone turnover in adults with hepatitis B virus (HBV)-HIV co-infection with high prevalence of tenofovir-based antiretroviral therapy use.
    HIV Med. 2022 May 16. doi: 10.1111/hiv.13322.
    >> Share

  71. MAGGIOLO F, Rizzardini G, Molina JM, Pulido F, et al
    Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people >/=65 years of age.
    HIV Med. 2022 May 8. doi: 10.1111/hiv.13319.
    >> Share

    March 2022
  72. RYOM L, De Miguel R, Cotter AG, Podlekareva D, et al
    Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021.
    HIV Med. 2022 Mar 25. doi: 10.1111/hiv.13268.
    >> Share

  73. GEDELA K, Rajus N, Luis H, Fridayantara WD, et al
    Antiretroviral drug switches to zidovudine-based regimens and loss to follow-up during the first COVID-19 lockdown in Bali, Indonesia.
    HIV Med. 2022 Mar 21. doi: 10.1111/hiv.13298.
    >> Share

  74. DING H, Xu J, Liu J, Wang Q, et al
    Outcomes of persistent low-level viremia among HIV patients on antiretroviral therapy: A prospective cohort study.
    HIV Med. 2022;23 Suppl 1:64-71.
    >> Share

  75. BAI R, Lv S, Hua W, Su B, et al
    Factors associated with human immunodeficiency virus-1 low-level viremia and its impact on virological and immunological outcomes: A retrospective cohort study in Beijing, China.
    HIV Med. 2022;23 Suppl 1:72-83.
    >> Share

  76. ALVAREZ H, Rava M, Martinez C, Portilla J, et al
    Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort.
    HIV Med. 2022 Mar 1. doi: 10.1111/hiv.13265.
    >> Share

    December 2021
  77. REEVES I, Cromarty B, Deayton J, Dhairyawan R, et al
    British HIV Association guidelines for the management of HIV-2 2021.
    HIV Med. 2021;22 Suppl 4:1-29.
    >> Share

    September 2021
  78. WONG IKJ, Grulich AE, Poynten IM, Polizzotto MN, et al
    Time trends in cancer incidence in Australian people living with HIV between 1982 and 2012.
    HIV Med. 2021 Sep 28. doi: 10.1111/hiv.13179.
    >> Share

  79. VENKATESH KK, Edmonds A, Westreich D, Dionne-Odom J, et al
    Associations between HIV, antiretroviral therapy and preterm birth in the US Women's Interagency HIV Study, 1995-2018: a prospective cohort.
    HIV Med. 2021 Sep 12. doi: 10.1111/hiv.13171.
    >> Share

    July 2021
  80. SHARMA I
    Interrogating the impact of combination antiretroviral therapies on HIV-associated neurocognitive disorders.
    HIV Med. 2021 Jul 21. doi: 10.1111/hiv.13142.
    >> Share

    June 2021
  81. ZHABOKRITSKY A, Szadkowski L, Burchell AN, Cooper C, et al
    Immunological and virological response to initial antiretroviral therapy among older people living with HIV in the Canadian Observational Cohort (CANOC).
    HIV Med. 2021 Jun 1. doi: 10.1111/hiv.13125.
    >> Share

    February 2021
  82. JESPERSEN NA, Axelsen F, Dollerup J, Norgaard M, et al
    The burden of non-communicable diseases and mortality in people living with HIV (PLHIV) in the pre-, early- and late-HAART era.
    HIV Med. 2021 Feb 28. doi: 10.1111/hiv.13077.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016